Veru Inc.
VERU · Nasdaq · United States
Share price · VERU
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VERU's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+7.9%
- 15 Oct 2026+14.6%
Nothing announced by VERU that day or the session before.
- 4 Jun 2026+88.0%
- 3 Jun 2026-4.3%
Nothing announced by VERU that day or the session before.
- 22 May 2026+5.9%
Nothing announced by VERU that day or the session before.
- 14 May 2026-7.5%
- 5 Feb 2026-11.5%
- 16 Jan 2026+11.2%
Nothing announced by VERU that day or the session before.
Share of unusual movement by asset
For each asset, the share of VERU's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Androgen receptor (selective)Small molecule | Obesity |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.3M | $24M | $7.0M-$5.5M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $3.1M | $28M | $2.7M-$8.9M operating cash flow | report ↗ |
| 2025-Q4 | — | $1.3M | $33M | $5.3M-$6.2M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $3.0M | $15M | $7.3M-$5.5M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $3.9M | $20M | $7.9M-$7.7M operating cash flow | report ↗ |
| 2024-Q4 | — | $5.7M | $27M | $8.9M-$11M operating cash flow | report ↗ |
| 2024-Q2 | $4.0M | $4.9M | $29M | $11M-$5.7M operating cash flow | report ↗ |
| 2024-Q1 | $4.1M | $3.0M | — | $10M-$5.7M operating cash flow | report ↗ |
| 2023-Q4 | $2.1M | $1.6M | — | $8.3M-$6.0M operating cash flow | report ↗ |
| 2023-Q2 | $3.3M | $2.9M | — | —-$18M operating cash flow | report ↗ |
| 2023-Q1 | $6.6M | $23M | — | $39M-$26M operating cash flow | report ↗ |
| 2022-Q4 | $2.5M | $19M | — | $37M-$35M operating cash flow | report ↗ |
| 2022-Q2 | $9.6M | $18M | — | $22M-$14M operating cash flow | report ↗ |
| 2022-Q1 | $13M | $16M | — | $14M-$4.0M operating cash flow | report ↗ |
| 2021-Q4 | $14M | $10M | — | $6.4M-$8.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $16M | $16M | $5.7M-$30M operating cash flow | report ↗ |
Veru did not disclose revenue for fiscal 2025, with prior-year revenue of $16.89M. R&D spend was $15.59M, up 21.7% YoY from $12.81M, while cash, cash equivalents and restricted cash were $15.79M at September 30, 2025, versus $24.9M at fiscal 2024 year-end. Net loss was $22.73M, narrowed from $37.8M in fiscal 2024.
The company highlighted positive Phase 2b QUALITY results for enobosarm in combination with a GLP-1 RA and said the FDA provided regulatory clarity that incremental weight loss is an acceptable approvable primary endpoint, with key secondary endpoints on physical function and body composition. Veru plans to initiate the Phase 2b PLATEAU study in calendar Q1 2026, with interim results anticipated in Q1 2027. After fiscal year end, the company completed a public offering for net proceeds of approximately $23.4 million.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($5K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-13 | BARNETTE K GARY · Chief Scientific Officer | Open-market purchase | 1,800 | $2.69 | $5K | Form 4 |
| 2026-05-04 | FISCH HARRY · director, Chief Corporate Officer | Award / grant (derivative) | 160,000 | — | — | Form 4 |
| 2026-05-04 | BARNETTE K GARY · Chief Scientific Officer | Award / grant (derivative) | 160,000 | — | — | Form 4 |
| 2026-05-04 | Lu Lucy · director | Award / grant (derivative) | 104,000 | — | — | Form 4 |
| 2026-05-04 | Rankowitz Michael L · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-05-04 | Hyun Grace · director | Award / grant (derivative) | 97,000 | — | — | Form 4 |
| 2026-05-04 | Katzovitz Loren Mark · director | Award / grant (derivative) | 102,000 | — | — | Form 4 |
| 2026-05-04 | Greco Michele · Chief Admin Officer and CFO | Award / grant (derivative) | 164,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 3.4M shares ($7.1M, 20.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 1,000,000 | $2.2M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 539,382 | $1.2M |
| 3 | OPPENHEIMER & CO INC | 196,300 | $434K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 184,622 | $408K |
| 5 | Summit Financial, LLC | 151,783 | $335K |
| 6 | MILLENNIUM MANAGEMENT LLC | 150,401 | $332K |
| 7 | Ikarian Capital, LLC | 133,517 | $295K |
| 8 | BlackRock, Inc. | 114,169 | $252K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 80,653 | $178K |
| 10 | CHOREO, LLC | 75,263 | $166K |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 69,250 | $153K |
| 12 | RAYMOND JAMES FINANCIAL INC | 67,561 | $149K |
| 13 | STATE STREET CORP | 55,004 | $122K |
| 14 | BLAIR WILLIAM & CO/IL | 48,000 | $106K |
| 15 | CITADEL ADVISORS LLC | 44,482 | $98K |